BIO

EX-99.1

2 bio-8k842026xex991.htm

EX-99.1

Document

Exhibit 99.1

Press Release

Bio-Rad Reports Second-Quarter 2026 Financial Results

HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating cash flow, and repurchased approximately $32 million of shares. We are reaffirming our full-year outlook, and remain focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation.”

Financial Results Highlights

GAAP Results

Q2 2026Q2 2025

Net sales (millions) $651.0 $651.6

Gross margin53.1 %53.0 %

Income from operations (millions) $72.6 $77.1

Net income (millions)$371.4 $317.8

Income per diluted share$13.85 $11.67

Net cash from operations (millions) $98.7 $116.5

Non-GAAP Results

Q2 2026Q2 2025

Net sales (millions) $651.0 $651.6

Gross margin53.9 %53.7 %

Income from operations (millions) $81.1 $88.6

Net income (millions)$70.2 $71.0

Income per diluted share$2.62 $2.61

Free cash flow (millions) $66.7 $70.8

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting”. A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Second-Quarter 2026 Results

Second-quarter 2026 total net sales were $651.0 million compared to $651.6 million reported for the second quarter of 2025, essentially flat. On a currency-neutral basis, sales decreased 1.9 percent compared to the same period in 2025, driven by lower sales in Life Science segment.

Life Science segment net sales for the second quarter were $252.0 million, a decrease of 4.1 percent compared to the same period in 2025. On a currency-neutral basis, Life Science segment sales decreased 5.1 percent compared to the same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by ongoing challenges in the academic research market.

1

Clinical Diagnostics segment net sales for the second quarter were $399.0 million, an increase of 2.6 percent compared to the same period in 2025. On a currency-neutral basis, Clinical Diagnostics segment sales increased 0.3 percent compared to the same period in 2025. The currency-neutral year-over-year sales increase was primarily driven by growth in quality systems, diabetes and blood typing products, partially offset by lower sales of infectious disease products.

During the second quarter of 2026, the Company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $371.4 million, or $13.85 per share, on a diluted basis, compared to a net income of $317.8 million, or $11.67 per share, on a diluted basis, reported for the same period in 2025.

The effective tax rate for the second quarter of 2026 was 31.5 percent, compared to 23.2 percent for the same period in 2025. The effective tax rate reported in these periods was primarily affected by the change in fair market value of our equity securities, shifts in the geographical mix of earnings and enactment of new tax legislation during the period.

The non-GAAP effective tax rate for the second quarter of 2026 was 18.3 percent, compared to 22.7 percent for the same period in 2025. The lower rate in 2026 was driven by geographical mix of earnings.

Full-Year 2026 Financial Outlook

For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.

Conference Call and Webcast

Management will discuss the Company’s second quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on August 4, 2026. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.

A live webcast of the conference call will also be available in the “Investor Relations” section of the Company’s website under “Events & Presentations” at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

BIO-RAD is a trademark

EX-99.1

2 bio-8k4302026xex991.htm

EX-99.1

Document

Exhibit 99.1

Press Release

Bio-Rad Reports First-Quarter 2026 Financial Results

HERCULES, Calif.—April 30, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026.

Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the Middle East, reported sales grew 1.1% year-over-year. Against this backdrop, we generated strong operating cash flow, $78 million in free cash flow, and repurchased approximately 176 thousand shares, highlighting the quality and long-term durability of our business. We continue to evaluate and optimize our organization to create more value for customers, and ultimately, shareholders."

Financial Results Highlights

GAAP Results

Q1 2026Q1 2025

Net sales (millions) $592.1 $585.4

Gross margin52.3 %52.3 %

Income from operations (millions) $34.1 $23.7

Net income (loss) (millions)$(527.1)$64.0

Income (loss) per diluted share$(19.55)$2.29

Net cash from operations (millions) $108.1 $129.9

Non-GAAP Results

Q1 2026Q1 2025

Net sales (millions) $592.1 $585.4

Gross margin53.1 %53.8 %

Income from operations (millions) $39.3 $63.0

Net income (millions)$50.9 $71.0

Income per diluted share$1.89 $2.54

Free cash flow (millions) $78.1 $95.5

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting”. A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

First-Quarter 2026 Results

First-quarter 2026 total net sales were $592.1 million, an increase of 1.1 percent compared to $585.4 million reported for the first quarter of 2025. On a currency-neutral basis, sales decreased 4.2 percent compared to the same period in 2025, driven by lower sales in both Life Science and Clinical Diagnostics segments.

Life Science segment net sales for the first quarter were $228.5 million, essentially flat compared to the same period in 2025. On a currency-neutral basis, Life Science segment sales decreased 4.3 percent compared to the same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by ongoing challenges in the academic research market, particularly in the Americas.

1

Clinical Diagnostics segment net sales for the first quarter were $363.6 million, an increase of 1.9 percent compared to the same period in 2025. On a currency-neutral basis, Clinical Diagnostics segment sales decreased 4.1 percent compared to the same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by the recent escalation of regional conflicts in the Middle East.

During the first quarter of 2026, the company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net loss of $527.1 million, or $19.55 per share, on a diluted basis, compared to a net income of $64.0 million, or $2.29 per share, on a diluted basis, reported for the same period in 2025.

The effective tax rate for the first quarter of 2026 was 23.6 percent, compared to 23.3 percent for the same period in 2025. The effective tax rate reported in these periods was primarily affected by the change in fair market value of our equity securities as well as shifts in the geographical mix of earnings.

The non-GAAP effective tax rate for the first quarter of 2026 was 22.6 percent, compared to 20.6 percent for the same period in 2025. The higher rate in 2026 was driven by geographical mix of earnings.

Updated Full-Year 2026 Financial Outlook

Bio-Rad is updating its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, compared to its prior expectation of growth of approximately 0.5 to 1.5 percent. The Company also expects an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior estimate of approximately 12.0 to 12.5 percent.

Conference Call and Webcast

Management will discuss the company’s first quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on April 30, 2026. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.

A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Present

EX-99.1

2 bio-8k2122026xex991.htm

EX-99.1

Document

Exhibit 99.1

Press Release

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

HERCULES, Calif.—February 12, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025.

Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market adoption of our expanded ddPCR™ product portfolio. As we enter 2026, we remain committed to improving overall performance.”

Financial Results Highlights

GAAP Results

Q4 2025Q4 2024Full-Year 2025Full-Year 2024

Revenue (millions)$693.2 $667.5 $2,583.2 $2,566.5

Gross margin49.8 %51.2 %51.9 %53.7 %

Income (loss) from operations (millions)$(118.9)$58.4 $47.2 $269.0

Net income (loss) (millions)$720.0 $(715.8)$759.9 $(1,844.2)

Net income (loss) per diluted share$26.65 $(25.57)$27.85 $(65.36)

Non-GAAP Results

Q4 2025Q4 2024Full-Year 2025Full-Year 2024

Revenue (millions)$693.2 $667.5 $2,583.2 $2,566.5

Gross margin52.5 %53.9 %53.3 %55.0 %

Income from operations (millions)$83.0 $92.1 $311.6 $331.3

Net income (millions)$67.7 $81.2 $270.5 $291.1

Net income per diluted share$2.51 $2.90 $9.92 $10.31

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting.” A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Fourth-Quarter 2025 Results

Fourth-quarter 2025 total net sales were $693.2 million, an increase of 3.9 percent compared to $667.5 million reported for the fourth quarter of 2024. On a currency neutral basis, quarterly sales increased 1.7 percent compared to the same period in 2024. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment.

Life Science segment net sales for the fourth quarter were $267.9 million, a decrease of 2.6 percent compared to the same period in 2024. On a currency neutral basis, Life Science segment sales decreased by 4.0 percent compared to the same quarter in 2024, driven by constrained academic research and biotech funding. Currency neutral sales decreased in the Americas partially offset by increased sales in EMEA and Asia Pacific.

1

Clinical Diagnostics segment net sales for the fourth quarter were $425.3 million, an increase of 8.4 percent compared to the same period in 2024. On a currency neutral basis, net sales increased 5.6 percent versus the same quarter last year. The currency neutral sales increase was primarily driven by quality controls, blood typing, and diabetes products, partially offset by lower sales of infectious disease products. Currency neutral sales increased in all regions.

During the fourth quarter of 2025, the Company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $720.0 million, or $26.65 per share, on a diluted basis, partially offset by the $172.8 million impairment of purchased intangibles and related items, compared to a net loss of $715.8 million, or $25.57 per share, on a diluted basis, reported for the same period of 2024.

The effective tax rate for the fourth quarter of 2025 was 22.5 percent, compared to 21.2 percent for the same period in 2024. The effective tax rate reported in these periods was affected by the change in fair market value of our investment in Sartorius AG as well as shifts in the geographical mix of earnings.

The non-GAAP effective tax rate for the fourth quarter of 2025 was 25.3 percent, compared to 20.9 percent for the same period in 2024. The higher rate in 2025 was primarily driven by shifts in the geographical mix of earnings and implementation of new tax legislation.

Full-Year 2025 Results

On a reported basis, net sales for the full-year of 2025 increased 0.7 percent to $2,583.2 million, compared to $2,566.5 million for the prior year. On a currency neutral basis, full-year 2025 revenue remained essentially flat year-over-year.

Full-year 2025 reported net sales for the Life Science segment were $1,021.1 million, a decrease of 1.3 percent compared to the prior year on a currency neutral basis, primarily driven by the constrained academic research and biotech funding environment.

Full-year 2025 reported net sales for the Clinical Diagnostics segment were $1,562.1 million, an